Company profile
Nanoscope Therapeutics Inc.
Bringing Back the Light of Hope
- Industry
- Biotechnology Research
- Employees
- 50
- Headquarters
- Dallas, Texas
- Founded
- 2017
- LinkedIn followers
- 9,718
- Office locations
- 1
Nanoscope Therapeutics Inc. company summary
Nanoscope Therapeutics Inc. is a company in the Biotechnology Research industry, headquartered in Dallas, Texas, founded in 2017. On LinkedIn the company has around 50 employees and 9,718 followers. Warmrank detected 32 technologies across 21 categories on nanostherapeutics.com, including Atlassian, Cloudflare, Cloudflare Bot Management.
What technology does Nanoscope Therapeutics Inc. use?
Warmrank detected 32 technologies on nanostherapeutics.com, last checked July 2026. Click any tool to see other companies that use it.
JavaScript libraries
Magnific Popup
Mailcheck
jQuery
jQuery MigrateMiscellaneous
HTTP/3
Open Graph
RSSFont scripts
Font Awesome
Google Font API
Cloudflare Bot ManagementWordPress plugins
ExactMetrics
WPFormsAnalytics
Google AnalyticsCDN
Cloudflare
WordPressDatabases
MySQLDigital asset management
DropboxGeolocation
ipapi.coJavaScript frameworks
GSAPPage builders
ElementorShow 8 more technologiesShow fewer technologies
Performance
Priority HintsProgramming languages
PHP
Yoast SEOSSL/TLS certificate authorities
Tag managers
Google Tag ManagerVideo players
YouTubeWebmail
Microsoft 365Widgets
Slider RevolutionAbout Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for retinitis pigmentosa (RP) (NCT04945772), a rolling BLA submission to the FDA has been initiated. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2025. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD and EMA Orphan Drug Designation to cover non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. A Phase 2 program for MCO in geographic atrophy (GA) patients is expected to start by the end of 2025. Other IND-ready programs include Leber congenital amaurosis (LCA). 8.25
Where is Nanoscope Therapeutics Inc. located?
Nanoscope Therapeutics Inc. lists 1 location.
Compare companies similar to Nanoscope Therapeutics Inc.
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Nanoscope Therapeutics Inc. nanostherapeutics.com | Biotechnology Research | 50 | 2017 | Dallas, Texas |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Nanoscope Therapeutics Inc.
What does Nanoscope Therapeutics Inc. do?
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for retinitis pigmentosa (RP) (NCT04945772), a rolling BLA submission to the FDA has been initiated. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2025. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD and EMA Orphan Drug Designation to cover non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. A Phase 2 program for MCO in geographic atrophy (GA) patients is expected to start by the end of 2025. Other IND-ready programs include Leber congenital amaurosis (LCA). 8.25
What technology does Nanoscope Therapeutics Inc. use?
Warmrank detected 32 technologies on nanostherapeutics.com, including Atlassian, Cloudflare, Cloudflare Bot Management, Dropbox, Elementor, ExactMetrics, Font Awesome, GSAP.
How many employees does Nanoscope Therapeutics Inc. have?
Nanoscope Therapeutics Inc. has around 50 employees on LinkedIn.
Where is Nanoscope Therapeutics Inc. headquartered?
Nanoscope Therapeutics Inc. is headquartered in Dallas, Texas.
When was Nanoscope Therapeutics Inc. founded?
Nanoscope Therapeutics Inc. was founded in 2017.
Build a lead list from companies like Nanoscope Therapeutics Inc.
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.